Cargando…

Current and Emerging Approaches for Hepatic Fibrosis Treatment

Liver fibrosis resulting from chronic liver injury is a key factor to develop liver cirrhosis and risk of hepatocellular carcinoma (HCC) which are major health burden worldwide. Therefore, it is necessary for antifibrotic therapies to prevent chronic liver disease progression and HCC development. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jingguo, Tuo, Biguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310447/
https://www.ncbi.nlm.nih.gov/pubmed/34326871
http://dx.doi.org/10.1155/2021/6612892
_version_ 1783728764668084224
author Li, Jingguo
Tuo, Biguang
author_facet Li, Jingguo
Tuo, Biguang
author_sort Li, Jingguo
collection PubMed
description Liver fibrosis resulting from chronic liver injury is a key factor to develop liver cirrhosis and risk of hepatocellular carcinoma (HCC) which are major health burden worldwide. Therefore, it is necessary for antifibrotic therapies to prevent chronic liver disease progression and HCC development. There has been tremendous progress in understanding the mechanisms of liver fibrosis in the last decade, which has created new opportunities for the treatment of this condition. In this review, we aim to make an overview on information of different potential therapies (drug treatment, cell therapy, and liver transplantation) for the liver fibrosis and hope to provide the therapeutic options available for the treatment of liver fibrosis and discuss novel approaches.
format Online
Article
Text
id pubmed-8310447
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-83104472021-07-28 Current and Emerging Approaches for Hepatic Fibrosis Treatment Li, Jingguo Tuo, Biguang Gastroenterol Res Pract Review Article Liver fibrosis resulting from chronic liver injury is a key factor to develop liver cirrhosis and risk of hepatocellular carcinoma (HCC) which are major health burden worldwide. Therefore, it is necessary for antifibrotic therapies to prevent chronic liver disease progression and HCC development. There has been tremendous progress in understanding the mechanisms of liver fibrosis in the last decade, which has created new opportunities for the treatment of this condition. In this review, we aim to make an overview on information of different potential therapies (drug treatment, cell therapy, and liver transplantation) for the liver fibrosis and hope to provide the therapeutic options available for the treatment of liver fibrosis and discuss novel approaches. Hindawi 2021-07-17 /pmc/articles/PMC8310447/ /pubmed/34326871 http://dx.doi.org/10.1155/2021/6612892 Text en Copyright © 2021 Jingguo Li and Biguang Tuo. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Li, Jingguo
Tuo, Biguang
Current and Emerging Approaches for Hepatic Fibrosis Treatment
title Current and Emerging Approaches for Hepatic Fibrosis Treatment
title_full Current and Emerging Approaches for Hepatic Fibrosis Treatment
title_fullStr Current and Emerging Approaches for Hepatic Fibrosis Treatment
title_full_unstemmed Current and Emerging Approaches for Hepatic Fibrosis Treatment
title_short Current and Emerging Approaches for Hepatic Fibrosis Treatment
title_sort current and emerging approaches for hepatic fibrosis treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310447/
https://www.ncbi.nlm.nih.gov/pubmed/34326871
http://dx.doi.org/10.1155/2021/6612892
work_keys_str_mv AT lijingguo currentandemergingapproachesforhepaticfibrosistreatment
AT tuobiguang currentandemergingapproachesforhepaticfibrosistreatment